Inhibitors of epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have become stalwarts in the management of metastatic CRC, albeit their efficacy is often thwarted by intrinsic or acquired resistance mechanisms.5 Concurrently, the dawn of precision medicine has signaled a shift from the one-size-fits-all approach toward a more bespoke treatment paradigm. The gene discussed is EGFR; the disease is colorectal carcinoma.